Thorough knowledge of anti-diabetes medications found to lead to better management, adherence.

When combined with diet and exercise, GLP-1 medication showed significant weight loss compared to liraglutide and placebo, a new study finds.

New findings compare treatment with patients taking two or more glucose-lowering agents.

In your experience, what have most studies about CGM demonstrated?

- HbA1c is lower in CGM users regardless of age or type of insulin delivery.
- Patients using MDI + CGM have greater reductions in HbA1c than those using CSII + CGM.
- Reductions in glycemic variability and time spent in hypoglycemia are not significantly different between SAP and MDI/RT-CGM therapy groups.
- All of the above

Follow the link to see how you and your colleagues compare.

Which is not a side effect of SGLT-2 Inhibitors?

A. Kidney failure
B. Hyperkalemia
C. Ketoacidosis
D. Hypertension
E. Increased cholesterol levels
F. Serious urinary tract infections
G. Increased bladder cancer risk
H. Serious allergic reactions

Follow the link for the answer.

iFORA - Diabetes Manager app designed to make busy lives easier to manage. iFORA comes with advanced mobile technology, sleek interface design, detailed and yet careful data management tools to assist you in better diabetes management. The easy-to-use tools can help you better understand how your blood glucose level interlinks with a positive self-monitoring process through recording, tracking, seeing your diabetes information in statistic trend graphs, target pie charts and exporting data to Fora TeleHealth solution to share with your doctor.

In this week's Homerun Slides,  we conclude this series with blinded versus unblinded CGM and CGM utilization.

Several studies, culminating in the large and definitive Diabetes Control and Complications Trial and the United Kingdom Prospective Diabetes Study have established that hyperglycemia is the major risk factor for microvascular diabetic complications. Chronic hyperglycemia also seems to be a significant and independent, albeit weaker risk factor for macrovascular disease. Other adverse consequences of hyperglycemia include an increased susceptibility to infections.

FDA issues new warning regarding SGLT2 inhibitors after 12 cases of rare necrotizing fasciitis emerge.

Investigators find patients treated with GLP-1 drug had significantly lower number of amputations compared to placebo group.